Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Konan E Beke"'
Autor:
Christopher E. Jensen, Allison M. Deal, Alexis C. Wardell, Hillary M. Heiling, Konan E. Beke, Daniel R. Richardson
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
Externí odkaz:
https://doaj.org/article/eaca7864b23d41898c37e806bbeb12ed
Autor:
Christopher E. Jensen, Hilary M. Heiling, Konan E. Beke, Allison M. Deal, Ashley L. Bryant, Lorinda A. Coombs, Matthew C. Foster, Daniel R. Richardson
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Time at home is a critically important outcome to adults with acute myeloid leukemia (AML) when selecting treatment; however, no study to date has adequately described the amount of time older adults spend at home following initiation of chemotherapy
Externí odkaz:
https://doaj.org/article/29e81864212045a7b9ecf9e5a0df40a2
Autor:
Christopher Edward Jensen, Hillary M Heiling, Konan E Beke, Allison Mary Deal, Ashley Leak Bryant, Lorinda A Coombs, Matthew Charles Foster, Daniel R. Richardson
Publikováno v:
Journal of Clinical Oncology. 40:376-376
376 Background: Older adults with acute myeloid leukemia (AML) have identified home time (HT) as a critical outcome influencing their treatment selection. However, few studies have characterized HT in this disease setting. Methods: We conducted a ret
Autor:
Konan E. Beke, Allison M. Deal, Daniel R. Richardson, Lorinda A. Coombs, Ashley Leak Bryant, Matthew C. Foster, Hillary M. Heiling, Christopher E. Jensen
Publikováno v:
Blood. 138:281-281
Introduction The prognosis for older adults with acute myeloid leukemia (AML) is poor. Of approximately 12,000 adults age ≥ 60 diagnosed with AML in the U.S. annually, less than 40% survive 1 year from diagnosis. Prior research has shown that adult
Autor:
Daniel R. Richardson, Christopher E. Jensen, Allison M. Deal, Konan E. Beke, Hillary M. Heiling
Publikováno v:
Blood. 138:1981-1981
Introduction: Recent analyses have demonstrated that race and geographic area are important factors for outcomes in acute myeloid leukemia (AML) patients under the age of 60. Older patients with AML often receive outpatient therapy aimed at prolongin